Home > News & Media > News
Communication starts here.
2023/03
TWi officially launches its Testosterone Topical Solution CIII (Equivalent to Axiron®) in TWi label
2023/03
TWi’ ANDA for Diltiazem HCL SR Capsules (equivalent to Cardizem SR®) has been officially approved by US FDA
2023/01
TWi officially launches its Guanfacine HCl Tablets in TWi label
2022/12
TWi’ ANDA for Dicyclomine Hydrochloride Capsule (equivalent to BENTYL ®) has been officially approved by US FDA
2022/12
TWi officially launches the merchandised Sorafenib Tosylate Tablet in the US market
2022/12
TWi officially launches its Fluphenazine HCl Tablets in TWi label
2022/06
TWi’ ANDA for Guanfacine HCl Tablets (equivalent to Tenex®) has been officially approved by US FDA
2022.04
TWi’ ANDA for Fluphenazine HCl Tablets (equivalent to Prolixin®) has been officially approved by US FDA
2022.03
TWi officially launches its Mycophenolic Acid Delayed-Release Tablets in TWi label
2021-01
TWi officially launches generic Dimethyl Fumarate DR Capsules in TWi label

 

Pages:1 - 2 - 3 - 4 - 5 - 6 - 7 - 8« Pre · Next »